UBS Group’s Diebold Nixdorf Incorporated DBD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-859,400
Closed -$1.03M 10301
2023
Q1
$1.03M Buy
+859,400
New +$1.91M ﹤0.01% 4073
2022
Q3
Sell
-204,500
Closed -$464K 11398
2022
Q2
$464K Buy
204,500
+174,800
+589% +$651K ﹤0.01% 4315
2022
Q1
$200K Buy
+29,700
New +$254K ﹤0.01% 5365
2019
Q2
Sell
-100
Closed -$1K 8268
2019
Q1
$1K Sell
100
-2,100
-95% -$14.7K ﹤0.01% 7590
2018
Q4
$5K Buy
+2,200
New +$7.89K ﹤0.01% 7577
2015
Q3
Sell
-800
Closed -$28K 8723
2015
Q2
$28K Hold
800
﹤0.01% 6563
2015
Q1
$28K Buy
+800
New +$27K ﹤0.01% 6625

Other funds holding DBD

UBS Group's DBD Position: Q2 2023 in Review

UBS Group sold out of Diebold Nixdorf Incorporated (DBD) in Q2 2023, closing a stake of 280,745 shares — an estimated $337K sold.

UBS Group first reported a position in DBD in Q4 2014 and held it in 34 quarters. The position peaked at $6.27M in Q1 2018. 7 funds tracked by Wall St. Rank hold DBD as of Q2 2023.

  • UBS Group reported no remaining Diebold Nixdorf Incorporated position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 280,745 Diebold Nixdorf Incorporated shares in Q2 2023, an estimated $337K.
  • UBS Group first reported a position in Diebold Nixdorf Incorporated in Q4 2014 and held it in 34 quarters.
  • UBS Group's Diebold Nixdorf Incorporated position peaked at $6.27M in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Diebold Nixdorf Incorporated as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.